Efficacy Study of Chemotherapy to Treat Advanced or Recurrent Endometrial Cancer
The purpose of this study is to treat advanced or recurrent endometrial cancer, paclitaxel-containing regimen is the preferred chemotherapeutic regimen which is selected by most physicians. Docetaxel may have similar efficacy and more favorable treatment related toxicity profile as tested in epithelial ovarian cancer trials. Therefore, the investigators aimed to evaluate the efficacy and safety of docetaxel plus cisplatin in patients with advanced or recurrent endometrial cancer.
Advanced or Recurrent Endometrial Cancer
DRUG: Doctaxel|DRUG: Cisplatin
Response rate, 3 months after completion of study treatment
Progression-free survival, 2 years after completion of study treatment|Number of Participants with Adverse Events as a Measure of Safety and Tolerability, Before each chemotherapy, an expected average of 3 weeks|Quality of life, 3 months after completion of study treatment
The purpose of this study is to treat advanced or recurrent endometrial cancer, paclitaxel-containing regimen is the preferred chemotherapeutic regimen which is selected by most physicians. Docetaxel may have similar efficacy and more favorable treatment related toxicity profile as tested in epithelial ovarian cancer trials. Therefore, the investigators aimed to evaluate the efficacy and safety of docetaxel plus cisplatin in patients with advanced or recurrent endometrial cancer.